Relay Therapeutics, Inc. (RLAY)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | 677 | 7,679 | - | |
| Research and development expenses | 63,897 | 73,809 | 76,619 | |
| General and administrative expenses | 13,627 | 18,739 | 19,750 | |
| Change in fair value of contingent consideration liability | - | - | - | |
| Total operating expenses | 77,524 | 92,548 | 96,369 | |
| Loss from operations | -76,847 | -84,869 | -96,369 | |
| Interest income | 7,105 | 7,813 | 8,274 | |
| Other (expense) income | -633 | -9 | -10 | |
| Total other income, net | 6,472 | 7,804 | 8,264 | |
| Net loss | -70,375 | -77,065 | -88,105 | |
| Unrealized holding (loss) gain | -201 | 1,029 | 3,849 | |
| Total other comprehensive (loss) income | -201 | 1,029 | 3,849 | |
| Total comprehensive loss | -70,576 | -76,036 | -84,256 | |
| Net loss per share, basic | -0.41 | -0.46 | -0.63 | |
| Net loss per share, diluted | -0.41 | -0.46 | -0.63 | |
| Weighted average shares of common stock, basic | 171,264,622 | 169,233,155 | 140,229,056 | |